BMY - Bristol-Myers Squibb Company
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Bristol Myers Squibb (BMY) or argenex SE (ARGX). But which of these two stocks presents investors with the better value opportunity right now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Dollar General, Bristol-Myers and Equinor stand out after broker rating upgrades, backed by projected earnings growth and resilient U.S. equity markets.
There are blazing deals for some of the top healthcare stocks -- companies with proven track records and dividend yields as high as 6%.
Bristol Myers has faced patent cliffs in recent years, and there are more on the horizon. The company seems relatively well equipped to deal with this issue moving forward.
Bristol Myers' Camzyos gains a broader FDA label and strong sales growth, while emerging competitors and pipeline setbacks shape its cardiovascular outlook.
AbbVie continues to grow its revenue base by successfully transitioning from Humira to its next-generation immunology drugs. Bristol Myers Squibb maintains high net margins and offers a significant valuation discount compared to its peer.
Johnson & Johnson generates consistently higher quarterly revenue than Bristol-Myers Squibb, maintaining a clear lead in total dollars over the entire observed eight-quarter period without any interruption. Both companies experienced a gentle pattern of quarter-over-quarter revenue growth over the last two calendar years, though the exact quarterly figures occasionally fluctuated between consecutive reporting periods.
Four dividend stocks from Philip Morris to JPMorgan Chase have ex-dates landing within days, and missing the cutoff means the payout goes to the seller. The clock is already running.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care Movement.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CAMZYOS--U.S. FDA Approves Expanded Indication for BMS's CAMZYOS for the Treatment of Symptomatic oHCM in Adults and Pediatric Patients.
Bristol Myers Squibb has raised its dividend for 17 straight years, but a looming patent cliff on its biggest cash generator puts that streak on a collision course with reality in 2027.
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Bristol Myers Squibb (NYSE: BMY - Get Free Report) and Bausch Health Cos (NYSE: BHC - Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, dividends and valuation. Volatility and Risk Bristol Myers Squibb
Bristol Myers Squibb maintains a deep portfolio of oncology and immunology treatments while generating high levels of free cash flow. Eli Lilly and is seeing explosive revenue growth driven by its market-leading metabolic and injectable drug platforms.
Bristol Myers Squibb's stock price is up 42.5% in the past 12 months, yet it still trades at a discounted valuation. Investors remain uncertain about the company's efforts to replace legacy drug sales with the sale of new drug products.
Bristol Myers Squibb's Growth Portfolio sales rose 15% in the second quarter, and management raised its 2026 revenue guidance to $49 billion to $50 billion. Novo Nordisk expects 2026 adjusted sales to range from flat to down 6% at constant exchange rates, even after raising that outlook in August.
Long-term bond yields persist despite pressure and circular remedies. But investors looking for income can still find plenty of attractive opportunities with dividend-paying stocks that have healthy yields. “23 stocks pay huge dividends. They should be a better bet than treasuries.” —Barron's Weekly reported in October 2024. It's still true more than ever as 10-yr bonds yield >5%. Interviewed by Barron's, Steven Wieting, strategist at Citi Wealth, noted growing dividends benefit shareholders and identify companies with strong balance sheets. “Nobody can fake a dividend,” he said.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #IMS26--BMS Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial.
BMY, HALO, TGT, NEO and ROST stocks show how women-led companies are redefining growth with discipline, agility and results.